Consistent with our observations in MYCN-amplified neuroblastoma cells, the cytotoxic effects of Cas9D10A targeting an amplified locus were significantly reduced at many doses in the presence of PARP inhibitors (Supplementary Fig. 27A–C) or calpastatin (Supplementary Fig. 27D–F). Here, PARP1 is linked to neuroblastoma.